Keywords
proinflammatory cytokines
hypothalamic-pituitary-adrenal system
glucocorticosteroids
How to Cite
Abstract
In recent years, the SARS-CoV-2 pandemic has posed a significant challenge to global public health. Furthermore, infection with SARS-CoV-2 can result in acute respiratory distress syndrome due to excessive systemic inflammation, leading to multiple organ failure and eventual death. Furthermore, the challenge of reducing excessive systemic inflammation, specifically by decreasing the production of pro-inflammatory cytokines in response to SARS-CoV-2, remains unresolved. The use of glucocorticosteroids for SARS-CoV-2 infection remains controversial. Further research is required to support the routine use of steroids in intensive care protocols for SARS-CoV-2, as the current basis is insufficient. This review provides an analysis of literary sources, guidelines, and modern international recommendations on pathogenetic therapy of SARS-CoV-2 to prevent and eliminate hyperproduction of pro-inflammatory cytokines using glucocorticosteroid agents. The aim of this work is to analyse contemporary literary sources on the clinical and pharmacological justification for the use of glucocorticosteroids in clinical practice for SARS-CoV-2 infection. The scientific literature analysis indicates that glucocorticosteroid therapy cannot be recommended for routine use in therapeutic practice for patients with SARS-CoV-2 infection. Thus, with a mild course of SARS-CoV-2 infection, when the patient does not need oxygen support, glucocorticosteroids are contraindicated. Whereas in severe course, in acute respiratory distress syndrome with severe respiratory failure, their use is absolutely necessary, and they are recommended for mandatory use. There is a need for a generalised definition of the optimal glucocorticosteroid agent, including indications, dosage, and duration of use in SARS-CoV-2 infection therapy programs.
Keywords: systemic inflammatory reaction, proinflammatory cytokines, hypothalamic-pituitary-adrenal system, glucocorticosteroids.
References
Karatash AV, Bilanova LP, Bilash SM, Pronina OM, Bilash VP, Hryn KV, et al. Progress and problems of vaccination against coronarovirus infection COVID-19. Bulletin of problems biology and medicine. 2022;3(166):50-7. DOI: 10.29254/2077-4214-2022-3-166-50-58.
Elnoby AS. Clinical Consideration of Glucocorticoids in COVID-19. J Pharm Pract. 2021;34(2):181-2. DOI: 10.1177/0897190020987124. PMID: 33455524.
Alexaki VI, Henneicke H. The Role of Glucocorticoids in the Management of COVID-19. Horm Metab Res. 2021;53(1):9-15. DOI: 10.1055/a-1300-2550. PMID: 33207372.
Yarmola T, Tkachenko L, Pustovoyt H, Rustamian S, Talash V, Kostrikova Iu, et al. Hemodialysis versus peritoneal dialysis in COVID-19 clinical characteristics and outcomes: A single-center experience. Ukrainian Journal of Nephrology and Dialysis. 2023;1(77):40-8. DOI: 10.31450/ukrjnd.1(77).2023.06. [In Ukrainian].
Widen C, Gustafsson JA, Wikstrom AC. Cytosolic glucocorticoid receptor interaction with nuclear factor-kappa B proteins in rat liver cells. Biochem J. 2003;373(Pt_1):211-20. DOI: 10.1042/BJ20030175. PMID: 12672265.
Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic Effects of Glucocorticoids: An Updated View. Trends Pharmacol Sci. 2019;40(1):38-49. DOI: 10.1016/j.tips.2018.11.002. PMID: 30497693.
Vandewalle J, Libert C. Glucocorticoids in Sepsis: To Be or Not to Be. Front Immunol. 2020;11:1318. DOI: 10.3389/fimmu.2020.01318. PMID: 32849493.
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-47. DOI: 10.1038/nri.2017.1. PMID: 28192415.
Hadjadj J, Yatim N, Barnabei L, at least 3 more authors, then Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-24. DOI: 10.1126/science.abc6027. PMID: 32661059.
Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul. 2021;81:100818. DOI: 10.1016/j.jbior.2021.100818. PMID: 34303107.
Quatrini L, Ugolini S. New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol. 2021;18(2):269-78. DOI: 10.1038/s41423-020-00526-2. PMID: 32868909.
Bodnar VA, Koval TI, Kotelevska TM, Marchenko OG, Pryimenko NO, Syzova LM, Izyumska OM. Clinical characteristics of patients with severe and critical during the course of COVID-19. Bulletin of problems biology and medicine. 2023;3(170):39-52. DOI: 10.29254/2077-4214-2023-3-170-184-194.
Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(5):1003-7. DOI: 10.1007/s00210-021-02049-7. PMID: 33443616.
Yaqoob H, Greenberg D, Hwang F, Lee C, Vernik D, Manglani R et al. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. J Med Virol. 2022;94(1):349-56. DOI: 10.1002/jmv.27351. PMID: 34542192.
Normand ST. The RECOVERY Platform. N Engl J Med. 2021;384(8):757-8. DOI: 10.1056/NEJMe2025674. PMID: 32706531.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021;384(8):693-704. DOI: 10.1056/NEJ-Moa2021436. PMID: 32678530.
Li H, Yan B, Gao R, Ren J, Yang J. Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. Int Immunopharmacol. 2021;100:108121. DOI: 10.1016/j.intimp.2021.108121. PMID: 34492533.
Qiu T, Liang S, Dabbous M, Wang Y, Han R, Toumi M. Chinese guidelines related to novel coronavirus pneumonia. J Mark Access Health Policy. 2020;8(1):1818446. DOI: 10.1080/20016689.2020.1818446.
Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/ European Respiratory Society coordinated International Task Force (29 Jul 2020). Eur Respir Rev. 2020;29(157):200287. DOI: 10.1183/16000617.0287-2020. PMID: 33020069.
Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VCC, Edwards KM, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2022:ciac724. DOI: 10.1093/cid/ciac72421. PMID: 36063397.
Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022;60(1):2102532. DOI: 10.1183/13993003.02532-2021. PMID: 34824060.
Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-87. DOI: 10.1007/s00134-020-06022-5. PMID: 32224769.
Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids – an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-25. DOI: 10.1007/s12663-021-01532-1. PMID: 33716414.
Marik PE, Kory P, Varon J, Iglesias J, Meduri GU. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. Expert Rev Anti Infect Ther. 2021;19(2):129-35. DOI: 10.1080/14787210.2020.1808462.
Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;165(1):1-7. DOI: 10.5507/bp.2021.011. PMID: 33542545.
Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282-9. DOI: 10.1002/path.1440. PMID: 12845623.
Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136-47. DOI: 10.2353/ajpath.2007.061088. PMID: 17392154.
Leyendecker P, Ritter S, Riou M, Wackenthaler A, Meziani F, Roy C, et al. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol. 2021;31(2):895-900. DOI: 10.1007/s00330-020-07226-5. PMID: 32852586.
Frankel M, Feldman I, Levine M, Frank Y, Bogot NR, Benjaminov O, et al. Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report. J Clin Endocrinol Metab. 2020;105(12):dgaa487. DOI: 10.1210/clinem/dgaa487. PMID: 32738040.
Heidarpour M, Vakhshoori M, Abbasi S, Shafie D, Rezaei N. Adrenal insufficiency in coronavirus disease 2019: a case report. J Med Case Rep. 2020;14(1):134. DOI: 10.1186/s13256-020-02461-2. PMID: 32838801.
Teblick A, Langouche L, Van den Berghe G. Anterior pituitary function in critical illness. Endocr Connect. 2019;8(8):R131-43. DOI: 10.1530/EC-19-0318. PMID: 31340197.
Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;165(1):1-7. DOI: 10.5507/bp.2021.011. PMID: 33542545.
Panesar NS, Lam CW, Chan MH, Wong CK, Sung JJ. Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol. Eur J Clin Invest. 2004;34(5):382-4. DOI: 10.1111/j.1365-2362.2004.01347.x. PMID: 15147338.
State Register of Medicinal Products of Ukraine [Internet]. Available at: http://www.drlz.com.ua
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.